Abeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT
May 12, 2017 08:05 ET
|
Abeona Therapeutics Inc
--Positive dose response in central nervous system with 60.7% +/- 8.8% reduction of disease-causing heparan sulfate GAG observed in Cohort 2--Reduction of disease manifestation observed in decreased...
Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA
May 09, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, May 09, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting
May 08, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, May 08, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona to Present At Multiple Upcoming Conferences
April 20, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, April 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights
March 31, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 31, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing...
Abeona Therapeutics to Present at Multiple Upcoming Investor Conferences
March 13, 2017 08:15 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 13, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference
March 07, 2017 07:45 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 07, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) a leading clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress
February 21, 2017 07:48 ET
|
Abeona Therapeutics Inc
Company CEO and COO Presentations to be Held on Wednesday, February 22ndNEW YORK and CLEVELAND, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) a leading...
Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017
February 17, 2017 07:45 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO):ABO-102 gene therapy well-tolerated in 4 subjects (N=3 low dose, N=1 high dose) through 650 days...
Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017
February 07, 2017 07:45 ET
|
Abeona Therapeutics Inc
Multiple Oral Platform Presentations and Poster Sessions Highlighting Gene Therapy Programs, Tuesday, February 14th through Thursday, February 16th NEW YORK and CLEVELAND, Feb. 07, 2017 (GLOBE...